Jan Koedam

Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML

Martin Wermke, Sabrina Kraus, Armin Ehninger et al. · Blood · 2021 · 160 citations · Full text

Relapsed/refractory Aml, Automotive Electronics, Engineering +1

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme

Lieke H. van der Helm, Canan Alhan, Pierre W. Wijermans et al. · British Journal of Haematology · 2011 · 106 citations · Full text

Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts

Lieke H. van der Helm, Nic J.G.M. Veeger, Marinus van Marwijk Kooy et al. · Leukemia Research · 2013 · 34 citations · Full text

Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML

Gerhard Ehninger, Sabrina Kraus, Elisa Sala et al. · Blood · 2022 · 30 citations

Updated Results from a Phase I Dose Escalation Study of the Rapidly-Switchable Universal CAR-T Therapy UniCAR-T-CD123 in Relapsed/Refractory AML

Martin Wermke, Stephan Metzelder, Sabrina Kraus et al. · Blood · 2023 · 28 citations